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Abstract
Choroidal neovascularization (CNV) is a major cause of severe visual loss in patients with
age-related macular degeneration (AMD). Recently, itraconazole has shown potent and
dose-dependent inhibition of tumor-associated angiogenesis. We evaluated the anti-angio-
genic effect of itraconazole in a rat model of laser-induced CNV. After laser photocoagula-
tion in each eye to cause CNV, right eyes were administered intravitreal injections of
itraconazole; left eyes received balanced salt solution (BSS) as controls. On day 14 after
laser induction, fluorescein angiography (FA) was used to assess abnormal vascular leak-
age. Flattened retinal pigment epithelium (RPE)-choroid tissue complex was stained with
Alexa Fluor 594-conjugated isolectin B4 to measure the CNV area and volume. Vascular
endothelial growth factor receptor 2 (VEGFR2) mRNA and protein expression was deter-
mined 1, 4, 7, and 14 days after intravitreal injection by quantitative RT-PCR or Western
blot. VEGF levels were analyzed by enzyme-linked immunosorbent assay (ELISA). Intravi-
treal itraconazole significantly reduced leakage from CNV as assessed by FA and CNV area
and volume on flat mounts compared with intravitreal BSS (p = 0.002 for CNV leakage,
p<0.001 for CNV area and volume). Quantitative RT-PCR showed significantly lower
expression of VEGFR2 mRNA in the RPE-choroid complexes of itraconazole-injected eyes
than those of BSS-injected eyes on days 7 and 14 (p = 0.003 and p = 0.006). Western blots
indicated that VEGFR2 was downregulated after itraconazole treatment. ELISA showed a
significant difference in VEGF level between itraconazole-injected and BSS-injected eyes
on days 7 and 14 (p = 0.04 and p = 0.001). Our study demonstrated that intravitreal itracona-
zole significantly inhibited the development of laser-induced CNV in rats. Itraconazole had
anti-angiogenic activity along with the reduction of VEGFR2 and VEGF levels. Itraconazole
may prove beneficial for treating CNV as an alternative or adjunct to other therapies.
Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in older people in
industrialized countries [1]. Severe vision loss in patients with AMD is commonly due to
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choroidal neovascularization (CNV) [2]. Although the CNV pathogenesis is not clearly under-
stood, pathological angiogenesis mediated by growth factors, such as vascular endothelial
growth factor (VEGF) and fibroblast growth factor, is important in CNV development. These
factors induce activation of signaling pathways after binding receptors on endothelial cells.
Several key signaling mediators including phospholipase C, phosphatidylinositol-3 kinase, and
protein kinase C deliver angiogenic signals to stimulate endothelial cell proliferation, migra-
tion, and survival.
Currently available treatments for CNV include laser photocoagulation, photodynamic
therapy, and intravitreal injection of anti-VEGF drugs. Although these treatments are helpful
in reducing the risk of visual deterioration, they only improve vision in 6–33% of patients
[3,4]. In addition, patients often exhibit AMD recurrence and require repeated treatments.
Multiple intravitreal injections for months or years are associated with complications, such as
cataract, retinal detachment, and endophthalmitis, and increase treatment costs [5]. To
enhance the outcomes of CNV treatment and reduce patient costs, novel, alternative anti-
angiogenic drugs are being investigated.
Itraconazole is a triazole antifungal drug that inhibits the enzyme lanosterol 14-α-demethy-
lase, which is important in ergosterol synthesis in fungi. Previous studies reported that itraco-
nazole has anti-angiogenic effects in in vitro assays and murine models [6,7]. The anti-
angiogenic mechanism involves inhibiting the mammalian target of rapamycin (mTOR) path-
way in human umbilical vein endothelial cells (HUVEC), hedgehog signaling in NIH-3T3
cells, and N-glycosylation in macrophages [8–10]. Itraconazole also inhibits activation of
VEGF receptor 2 (VEGFR2), the receptor that is primarily responsible for angiogenesis [11].
Since itraconazole showed a dose-dependent inhibitory effect on endothelial cell proliferation,
migration, and tube formation stimulated by VEGFR2-mediated signaling, itraconazole might
be useful as an inhibitor of pathological angiogenesis. However, few studies have evaluated the
effect of itraconazole in ocular neovascular disorders [12].
In this study, we investigated the anti-angiogenic effect of itraconazole in a rat model of
laser-induced CNV, which is a widely used CNV model and is well-suited for assessing the
inhibitory effects of intraocular drugs [13].
Materials and methods
Animals
Male Brown Norway rats weighing 200–250 g (Orient Bio Inc., Seongnam, Korea) were fed
laboratory chow and water ad libitum and acclimated to the animal facilities at Kangbuk Sam-
sung Hospital under a 12-hour on/off light cycle for one week. All experiments were designed
and conducted in accordance with guidelines for animal use and ophthalmic research of the
Association for Research in Vision and Ophthalmology and were approved by the Institutional
Animal Care and Use Committee of Kangbuk Samsung Hospital, Sungkyunkwan University
School of Medicine (Permit Number: 201503079).
Induction of CNV
Before all procedures, animals were anesthetized with intraperitoneal zolazepam-tiletamine
(Zoletil1, Virbac, Carros, France) at 30 mg/kg and xylazine hydrochloride at 10 mg/kg. Pupils
were dilated with 0.5% tropicamide and 0.5% phenylephrine HCl. Proparacaine hydrochloride
0.5% was applied to anesthetize the cornea. Animals were positioned in front of a slit-lamp
biomicroscope, and the fundus was visualized using a slide glass. A 532-nm Nd:YAG laser
(Pattern Scan Laser, OptiMedica Corp., Santa Clara, CA, USA) was used to induce CNV by
rupturing the Bruch membrane. The laser parameters were 60-μm spot size, 30-ms exposure,
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and 320-mW power. Six laser burns were placed concentrically, two disc diameters from the
optic disc in both eyes of all animals. Subretinal bubbles indicated ruptured Bruch membranes.
Eyes with vitreous or subretinal bleeding or no bubble formation were excluded.
Preparation and intravitreal injection of itraconazole
Itraconazole 250 mg/25 ml (Sporanox1, Janssen Pharmaceuticals Inc., Buckinghamshire, UK)
was diluted to a final concentration of 100 μg/ml under sterile conditions. Itraconazole con-
centrations used in this study were previously reported to be nontoxic [14]. Immediately after
inducing CNV, intravitreal injection was performed in eyes with laser induction and normal
control eyes. Topical proparacaine hydrochloride 0.5% was applied to the eye surface, and an
initial hole was made with a 30-gauge needle 2.0 mm posterior to the limbus in the superotem-
poral quadrant. The eye was gently massaged with a cotton tip to remove prolapsed vitreous. A
32-gauge needle on a 50-μl Hamilton syringe was inserted into the mid-vitreous cavity through
the initial hole at a 45˚ angle to the scleral surface to avoid injuring the lens with the needle
[15]. Animals were given intravitreal injections of itraconazole 1 μg/10 μl in the right eye and
10 μl balanced salt solution (BSS) in the left eye. Before and immediately after injection, 0.5%
moxifloxacin hydrochloride ophthalmic solution (Vigamox1, Alcon, Fort Worth, Texas,
USA) was applied to the ocular surface.
Leakage assessment and CNV grading
On day 14 after laser induction, 12 rats underwent fluorescein angiography (FA) with a Hei-
delberg Retina Angiograph (HRA; Heidelberg Engineering, Heidelberg, Germany) at a view-
ing angle of 50 degrees. For a wider field of view, a 20-diopter lens was attached to the fundus
camera. For FA examinations, 0.3 ml of 10% sodium fluorescein (5 ml; Novartis Korea, Seoul,
Korea) was administered intraperitoneally, and photographs were taken by a single trained
operator using the Automatic Real Time (ART) module (Heidelberg Engineering, Heidelberg,
Germany) at 30 seconds and 1, 2, 5, 10, and 15 minutes after dye injection. Angiograms at
five-minute (±1 minute) phase were used for comparative analyses. Images were evaluated
according to grading criteria [16] by two retinal specialists (JHB and SCL) in a masked fashion.
CNV lesions were classified as grade 0 (no hyperfluorescence), grade I (hyperfluorescence
without leakage), grade IIA (hyperfluorescence in early or mid-transit images and late leak-
age), or grade IIB (bright hyperfluorescence in transit images and late leakage beyond lesions).
Grade IIB was defined as clinically significant. The proportions of grade IIB CNV lesions in
itraconazole- and BSS-injected eyes were compared.
Size measurement of CNV on choroidal mounts
On day 14 after inducing CNV, five rats were euthanized by cervical dislocation, and their eyes
were enucleated and fixed with 10% formalin for 2 hours. The cornea and lens were removed,
four radial cuts were made to flatten the tissue, and the neural retina was gently removed from
the eyecup. Retinal pigment epithelium (RPE)-choroid-sclera complexes were washed with
phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM
KH2PO4) and incubated in blocking solution (1% bovine serum albumin, 10% normal goat
serum, 0.5% Triton X-100 in PBS) for 30 minutes. Alexa Fluor 594-conjugated isolectin B4
(1:100, 1 mg/ml solution, lectin from Bandeiraea simplicifolia, Invitrogen, Carlsbad, CA, USA)
was applied to eyecups overnight at 4˚C in blocking solution. After washing with PBS, eyecups
were placed flat with the RPE-side facing up on microscope slides. Flat mounts were examined
by fluorescence microscopy (IX71; Olympus, Tokyo, Japan), and CNV images were captured
with a digital camera attached to the microscope. Under magnification of digital images, the
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borders of hyperfluorescent CNV lesions were manually outlined by a masked investigator
(HGY), and the area of CNV lesions on flat mounts was measured. For the measurements of
CNV volume, Z-stack images through the entire CNV lesion were taken at a constant intensity
by a laser confocal microscope (LSM510 META; Carl Zeiss, Jena, Germany). Image analysis
was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA),
and the average area and volume of the CNV lesions were used for evaluation.
Real-time quantitative polymerase chain reaction
On days 1, 4, 7, and 14 after intravitreal injection, RPE-choroid complexes were isolated from
three eyes from each group at each time point and stored at -80˚C until use. RT-qPCR was per-
formed with the StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA,
USA) as described elsewhere [17]. Total RNA was purified with RNeasy Mini Kits (Qiagen,
Valencia, CA, USA), and cDNA was prepared using SuperScript III first-strand synthesis kits
(Invitrogen, Carlsbad, CA, USA) with 0.5 μg total RNA according to the manufacturer’s rec-
ommendations. Quantitative PCR used primers specific for rat VEGFR2 and β-actin with
SYBR Premix Ex Taq (Takara Bio, Inc., Shiga, Japan). Primer sequences were rat VEGFR2
50-CTC CAT CTT TTG GTG GGA TG-30 (forward) and 50-AGG CCA CAG ACT CCC TGC
TTT TAC TG-30 (reverse) and rat β-actin 50-TGC CTG ACG GTC AGG TCA-30 (forward) and
50-CAG GAA GGA AGG CTG GAA G-30 (reverse). All RT-qPCR experiments were performed
in triplicate.
The housekeeping gene β-actin was an internal control, and VEGFR2 mRNA levels were
normalized against β-actin levels. The StepOnePlus real-time PCR system was used to analyze
data and obtain threshold cycle (CT) values according to the manufacturer’s instructions. The
ΔΔCT method was used to transform CT values into relative quantities with standard devia-
tions [18].
Western blot analysis
VEGFR2 expression was evaluated by Western blot. On days 1, 4, 7, and 14 after intravitreal
injection, RPE-choroid complexes (three eyes per group at each time point) were homoge-
nized with a bead beater at 4˚C in cell lysis buffer (Cell Signaling Technology, Danvers, MA,
USA). Samples were centrifuged at 14,000 rpm for 15 minutes at 4˚C, and protein concentra-
tions of the supernatants were measured with the Pierce™ Bicinchoninic Acid Protein Assay
Kit (Thermo Fisher Scientific, Inc., Rockford, IL, USA). Soluble proteins (30 μg per sample)
were boiled for 5 minutes and resolved by 10% SDS-PAGE. Proteins were electrotransferred to
0.45-μm-pore polyvinylidene fluoride membranes and blocked with 5% skim milk. Mem-
branes were blotted overnight with primary antibodies diluted in 0.1% bovine serum albumin
and 0.01% sodium azide in TBS-T for VEGFR2 (Novus Biologicals) and β-actin. After washing
three times with TBS-T, blots were incubated with horseradish peroxidase-conjugated second-
ary antibody (Cell Signaling Technology) for 1 hour at room temperature. Blots were washed
three times with TBS-T, and immunoreactive bands were visualized by enhanced chemilumi-
nescence. Relative intensities of immunoreactive bands were measured after normalization for
β-actin. Representative Western blots are shown after three independent experiments.
Enzyme-linked immunosorbent assay
VEGF protein was analyzed in enucleated eyes via enzyme-linked immunosorbent assay
(ELISA) 1, 4, 7, and 14 days after inducing CNV. The cornea and lens were removed, and the
retina was separated from the eyecup. Retinas were homogenized in cell lysis buffer and incu-
bated for 30 minutes on ice. Lysate was centrifuged at 14,000 rpm for 15 minutes at 4˚C.
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Supernatants were assayed using commercially available ELISA kits against rat VEGF (RayBio-
tech Inc., Norcross, GA, USA) according to the manufacturer’s protocols. Total protein con-
centrations were determined using the Pierce™ BCA Protein Assay Kit (Thermo Fisher
Scientific, Inc., Rockford, IL, USA) as the standard. VEGF concentrations were measured by
ELISA in triplicate.
Statistical analyses
All statistical analyses were performed with the statistical package PASW 18.0 (SPSS Inc., Chi-
cago, IL, USA). All values are mean ± standard deviation. Comparative analyses of two values
between groups were made with the unpaired t-test or the Mann-Whitney U test. FA image
grades were compared with a chi-square test. P< 0.05 was considered significant.
Results
Inhibition of CNV formation by itraconazole
To assess the inhibitory effect of itraconazole on CNV formation, FA and isolectin B4 staining
of RPE-choroid complex flat mounts were conducted on day 14 after inducing CNV. FA
showed that intravitreal itraconazole significantly reduced fluorescein leakage from CNV com-
pared with intravitreal BSS (Fig 1A). The incidence of grade IIB CNV lesions was significantly
lower in itraconazole-injected eyes (34.7%, 25 of 72 lesions) than in BSS-injected eyes (61.1%,
44 of 72 lesions) (p = 0.002, Fig 1B).
Fig 2A shows isolectin B4-stained endothelial cells for angiogenesis in flat mounts of the
RPE-choroid complex. CNV lesions were smaller in the itraconazole group than in the BSS
group. The mean CNV area was significantly reduced in itraconazole-injected eyes (18154 ±
8767 μm2, n = 30 lesions) compared with BSS-injected eyes (29762 ± 6376 μm2, n = 30 lesions;
p<0.001, Fig 2B). Similarly, the mean CNV volume was also significantly decreased in itraco-
nazole-injected eyes (1232 ± 284 x 103 μm3, n = 18 lesions) compared with BSS-injected eyes
(620 ± 151 x 103 μm3, n = 18 lesions; p<0.001, Fig 2C).
These results suggest that intravitreal itraconazole effectively suppresses CNV development
and reduces vascular leakage in rats.
Reduction of VEGFR2 mRNA and protein after itraconazole treatment
As VEGF-mediated signaling plays an important role in CNV development, we investigated
the mRNA and protein levels of VEGFR2, a key receptor for pathological angiogenesis stimu-
lated by VEGF. To determine whether itraconazole affected expression of VEGFR2 in a rat
model of laser-induced CNV, RT-qPCR was performed for VEGFR2 mRNA in the RPE-cho-
roid complex 1, 4, 7, and 14 days after laser induction. RT-qPCR showed that VEGFR2 mRNA
increased gradually at each time point. The relative expression of VEGFR2 mRNA was signifi-
cantly lower in itraconazole-injected eyes than in BSS-injected eyes on days 7 and 14 (p =
0.003 and p = 0.006, respectively; relative gene expression indicates the ratio of VEGFR2
mRNA levels relative to those in BSS-injected normal eyes, Fig 3A).
Similarly, Western blots on days 1, 4, 7, and 14 after inducing CNV indicated that itracona-
zole treatment prominently reduced the density of the VEGFR2 band in the RPE-choroid
complex of rat eyes compared to BSS (Fig 3B). These results suggest that itraconazole might
prevent the development of laser-induced CNV along with the reduction of VEGFR2 mRNA
and protein.
To evaluate the effects of itraconazole on the expression of VEGFR2 in normal rat eyes, RT-
qPCR was performed for VEGFR2 mRNA in the RPE-choroid complex 1, 4, and 7 days after
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intravitreal injection. The expression of VEGFR2 mRNA remained low in normal eyes, and
there was no significant difference in the relative expression level of VEGFR2 mRNA between
itraconazole-injected normal eyes and BSS-injected normal eyes at any time point (Fig 3C).
Reduction of VEGF level after itraconazole treatment
Because itraconazole inhibited VEGFR2 expression, we further evaluated whether itraconazole
affected the intraocular level of VEGF protein in laser-induced CNV. ELISA was performed
Fig 1. Representative fluorescein angiography (FA) of choroidal neovascularization (CNV) lesions. Six laser burns were introduced around the
optic disc of each eye. Immediately after inducing CNV, either itraconazole or balanced salt solution (BSS) was injected intravitreally. On day 14, FA was
conducted to assess leakage from CNV. (A) Midphase (5 ± 1 minutes) FA of eyes injected with itraconazole or BSS. Arrows, lesion grades of laser-induced
CNV: grade I, grade IIA, or grade IIB. (B) Percentage of grade 0, I, IIA (defined as no-to-moderate leakage), and IIB (considered clinically significant)
lesions in itraconazole-injected eyes (n = 12) and BSS-injected eyes (n = 12). **p = 0.002.
https://doi.org/10.1371/journal.pone.0180482.g001
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Fig 2. (A) Representative fluorescein microscopic photographs of flat mounts of the RPE-choroid complex stained with Alexa Fluor 594-conjugated
isolectin B4 from Bandeiraea simplicifolia on day 14 after inducing CNV in itraconazole-injected and BSS-injected eyes. (B and C) Reduced CNV area and
volume stained with isolectin B4 were significant in itraconazole-injected eyes compared with BSS-injected eyes. Values represent mean ± standard
deviation (***p<0.001). Scale bar = 200 μm.
https://doi.org/10.1371/journal.pone.0180482.g002
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with cleared lysates of retinal protein 1, 4, 7, and 14 days after inducing CNV. The mean nor-
malized VEGF levels in the retina increased considerably after laser induction, with the highest
VEGF level observed on day 7 in both groups. There were significant differences in retinal
VEGF levels between itraconazole-injected eyes and BSS-injected eyes on days 7 and 14 (p =
0.04 and p = 0.001, respectively, Fig 4). Itraconazole treatment was associated with reduction
of the retinal VEGF level in laser-induced CNV after 7 days.
Discussion
In this study, we identified a novel effect of itraconazole as an anti-angiogenic agent in sup-
pressing CNV development in rats. On day 14 after inducing CNV, intravitreal itraconazole
significantly reduced fluorescein leakage from CNV and the vascular budding area on flat
mounts of the RPE-choroid complex. Our results also demonstrated that VEGFR2 mRNA
and protein levels in the RPE-choroid complex were reduced in laser-induced CNV after
Fig 3. Inhibitory effect of itraconazole on VEGFR2 expression. (A) Quantitative analysis of VEGFR2 mRNA by RT-qPCR. After inducing CNV, either
itraconazole or BSS was injected into the vitreous cavity of rat eyes. On days 1, 4, 7, and 14 after injection, the RPE-choroid complexes were separated
and subjected to assay. VEGFR2 mRNA level increased gradually from day 1 to day 14. Relative VEGFR2 mRNA expression was significantly lower in
itraconazole (ICZ)-injected eyes than in BSS-injected eyes on days 7 and 14 (**p = 0.003 and **p = 0.006, respectively). (B) Western blots of the RPE-
choroid complex on days 1, 4, 7, and 14 after laser induction. The density of the VEGFR2 bands, as indicated by a black arrow, decreased in ICZ-injected
eyes compared to BSS-injected eyes at each time point. (C) RT-qPCR of RPE-choroid tissue in normal rat eyes injected either with ICZ or with BSS. The
level of VEGFR2 mRNA in normal eyes was low and not significantly different between ICZ-injected and BSS-injected normal eyes. Values are
mean ± standard deviation (n = 9 eyes per group at each time point). Relative gene expression indicates the ratio of VEGFR2 mRNA levels relative to
those in BSS-injected normal eyes.
https://doi.org/10.1371/journal.pone.0180482.g003
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intravitreal itraconazole. However, the reduction of VEGFR2 after intravitreal itraconazole
was not significant in normal rat eyes. This finding suggests that the inhibitory effect of itraco-
nazole occurs selectively in pathological angiogenesis. To our knowledge, this is the first report
demonstrating the effects of intravitreal itraconazole in a rat model of CNV.
Several studies have reported the potent anti-angiogenic activity of itraconazole, and multi-
ple phase II human clinical trials are currently ongoing to study itraconazole as a cancer treat-
ment [6–9,19]. A recent in vivo study reported that oral itraconazole inhibited the growth of
primary xenografts of human non-small cell lung cancer [7]. In addition, a noncomparative
randomized phase II clinical trial suggested that oral itraconazole had modest antitumor activ-
ity by downregulating hedgehog signaling in advanced prostate cancer [20]. Because of its
good safety profile as an antifungal drug and its relatively high serum levels, itraconazole is a
candidate anticancer drug. Given its promising results as an anticancer drug, itraconazole may
have efficacy in treating ocular pathological angiogenesis such as CNV. In our study, mean
CNV area was reduced by 39% in itraconazole-injected eyes compared to BSS-injected eyes,
which was similar to previous similar studies with other drugs. Recently, intravitreal treatment
of triamcinolone acetonide was reported to reduce the CNV area by 41.8% compared to vehi-
cle treatment in laser-induced CNV in mice, and eyes with intravitreal VEGF-TRAP showed a
significant 29.9% reduction in CNV area compared to controls in a mouse model of laser-
induced CNV [21,22].
The mechanisms of CNV pathogenesis are complicated and not fully understood. Multiple
signaling pathways are involved in CNV development. Chronic oxidative stress in the RPE
and photoreceptors increases HIF-1 levels, which activate the gene expression of angiogenic
growth factors, such as VEGF and platelet-derived growth factor [23,24]. However, increased
Fig 4. Effect of itraconazole on VEGF levels in laser-induced CNV. ELISA showed that the mean
normalized VEGF levels in the retina increased markedly after laser induction. The highest level of VEGF was
observed on day 7. There were significant differences in VEGF levels between itraconazole (ICZ)-injected
eyes and BSS-injected eyes on days 7 and 14 (*p = 0.04 and **p = 0.001, respectively). Values are
mean ± standard deviation (n = 9 eyes per group at each time point).
https://doi.org/10.1371/journal.pone.0180482.g004
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VEGF expression in RPE cells is not sufficient to cause CNV without abnormalities or defects
in Bruch’s membrane [25]. In addition to the angiogenic factors associated with CNV, the
extracellular matrix and surrounding cells facilitate survival and stabilize endothelial cells [26].
Animal studies showed that inflammatory cells such as macrophages play a critical role in cho-
roidal angiogenesis through the recruitment and activation in CNV lesions to release pro-
angiogenic factors [27,28]. Thus, considering the various pathogenic factors involved in CNV,
therapies targeting multiple participants in CNV pathogenesis would provide benefits beyond
a single-target therapy.
Itraconazole, like other azole antifungal drugs, inhibits lanosterol demethylation to ergos-
terol in fungi and to cholesterol in humans. Cellular cholesterol trafficking activates the mTOR
pathway regulating multiple environmental signals required for cell growth and proliferation
[8,29]. Therefore, itraconazole could interrupt endothelial cell proliferation by lowering choles-
terol levels and inhibiting mTOR [30]. However, inhibiting lanosterol 14-α-demethylase alone
is not sufficient to explain itraconazole’s anti-angiogenic properties because other azoles do not
inhibit endothelial cell proliferation [6,19]. In some studies, itraconazole potently and selectively
inhibited multiple key regulators of tumor angiogenesis in murine models and in vitro assays
using HUVECs and human dermal microvascular endothelial cells (HMEC-1) [7,31]. Further-
more, itraconazole potently inhibits the hedgehog signaling pathway, which is implicated in
angiogenesis [9,20]. In fact, blockade of the mTOR pathway or hedgehog signaling pathway has
proven to be effective in reducing CNV in rodent models [32,33]. Thus, the inhibition of those
pathways via itraconazole treatment may show efficacy in preventing CNV, but further investi-
gation is needed to determine its effect.
Itraconazole was reported to inhibit VEGFR2 glycosylation and autophosphorylation and
VEGF binding to VEGFR2, which might be important in inhibiting angiogenesis in vivo [11].
VEGF is critical for CNV development, and preclinical and clinical data suggest that the VEGF
pathway may be a primary therapeutic target for CNV treatment [34]. Blocking VEGF recep-
tors can provide another way to antagonize VEGF and can potentially block multiple VEGF
subtypes. Of the VEGF receptors, VEGFR2 is involved in almost all VEGF-mediated responses
in pathological angiogenesis [35–37]. Thus, inhibiting VEGFR2 expression could result in
anti-VEGF activity by preventing VEGF-mediated signaling, leading to suppression of laser-
induced CNV in rats. In our study, VEGFR2 was markedly expressed in RPE-choroid tissue 7
days after laser induction, and the inhibitory effect of itraconazole was prominent in the late
period when CNV typically began to form; itraconazole effectively prevented the development
of CNV. However, the reduction of VEGFR2 level after itraconazole treatment might result
from fewer VEGFR2-expressing cells in RPE-choroid tissue, rather than from lower VEGFR2
expression on endothelial cells. Our data could not confirm that VEGFR2 expression on en-
dothelial cells would be suppressed by itraconazole treatment. Considering the complicated
pathogenesis of CNV, the anti-angiogenic effects of itraconazole might have a common down-
stream target in vivo. Thus, how closely the effects are associated with one another and how
potently they inhibit angiogenesis with itraconazole treatment should be investigated.
Anti-VEGF agents such as ranibizumab and aflibercept inhibit intraocular VEGF activity
and are promising treatments for CNV from AMD. Given the multifactorial pathogenesis of
AMD, however, a single anti-VEGF agent may not always be effective and would require
monthly or bimonthly injections. The lack of therapeutic options for CNV and limitations
associated with anti-VEGF antibody therapies have led to the search for other anti-angiogenic
agents. Itraconazole is a well-tolerated and orally bioavailable drug that has a well-established
safety profile. Targeting multiple pathways might enhance the efficacy of itraconazole as an
anti-angiogenic agent. Therefore, itraconazole is a novel candidate for an alternative treatment
for CNV.
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In this study, we evaluated the ability of itraconazole to prevent CNV development when
administered shortly after laser induction. Many therapeutic modalities have been evaluated in
preventing laser-induced CNV [38–40]. However, patients with AMD who require treatment
have an established disease, and efficacy in a preventive model of CNV does not necessarily
correspond to the human disease. The treatment model for established CNV is more suitable
for assessing the efficacy of drug therapies. Thus, further studies are warranted to determine
the efficacy and proper dosage of intraocular itraconazole for treating CNV.
In summary, our study demonstrated that intravitreal itraconazole significantly inhibited
the development of laser-induced CNV in rats. Itraconazole had anti-angiogenic effects along
with the reduction of VEGFR2 and VEGF levels. Itraconazole may prove beneficial for treating
CNV as an alternative or adjunct to other therapies.
Supporting information
S1 Fig. Original uncropped Western blots of the RPE-choroid complex on days 1, 4, 7, and
14 after laser induction.
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